Clinical Trial Update: MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating AUM001 in combination with pembrolizumab or irinotecan for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• AUM001 (MNK inhibitor AUM001)
• Camptosar (irinotecan)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: AUM Biosciences Pte Ltd | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING